Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bayer AG | 1,003 |
| 2 | German Cancer Research Center | 130 |
| 3 | Dana Farber Cancer Institute Inc | 65 |
| 4 | Ferring Holding SA | 63 |
| 5 | Case Western Reserve University | 36 |
| 6 | Harvard University | 33 |
| 7 | Mass General Brigham Inc | 23 |
| 8 | Ceva Sante Animale SA | 21 |
| 9 | Aquestive Therapeutics Inc | 19 |
| 10 | Technion Israel Institute of Technology | 19 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 1,693 |
| 2 | A61P | Therapeutic activity (drug indications) | 1,684 |
| 3 | C07D | Heterocyclic compounds | 1,016 |
| 4 | C07K | Peptides | 126 |
| 5 | C07C | Acyclic and carbocyclic compounds | 86 |
| 6 | C07F | Organometallic compounds | 76 |
| 7 | Y02A | Climate change adaptation | 73 |
| 8 | G01N | Investigating / analysing materials | 72 |
| 9 | C07B | General methods of organic chemistry | 66 |
| 10 | C12Q | Measuring/testing involving enzymes | 64 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| DRUG-DEVICE UNIT CONTAINING QUINAGOLIDE | 2016 | Ferring Holding SA | 4 |
| DRUG-DEVICE UNIT CONTAINING QUINAGOLIDE | 2017 | 2 | |
| STEREOSELECTIVE SYNTHESIS OF INTERMEDIATES AND SYNTHESIS OF QUINAGOLIDS | 2024 | Ferring Holding SA | 0 |
| Pharmaceutical device unit containing quinagolide | 2023 | Ferring Holding SA | 0 |
| Drug-device unit containing quinagolide | 2016 | Ferring Holding SA | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Judith Brownell | Radboud University Nijmegen | 19 |
| 2 | P. Lacasse | Agriculture and Agri-Food Canada | 10 |
| 3 | Annamaria Colao | University of Naples Federico II | 10 |
| 4 | P Jaquet | Hôpital de la Timone | 9 |
| 5 | Diego Ferone | Federico II University Hospital | 9 |
| 6 | Francesca Sarnacchiaro | Federico II University Hospital | 8 |
| 7 | Gaetano Lombardi | University of Naples Federico II | 8 |
| 8 | S. Ollier | Agriculture and Agri-Food Canada | 7 |
| 9 | Carolina Di Somma | Federico II University Hospital | 7 |
| 10 | Antonella Di Sarno | Federico II University Hospital | 7 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Autoradiographic localization of dopamine D1 and D2 receptors in the brain of several mammalian species | 1990 | 213 | Neurotransmitter Receptor Influence on Behavior |
| Prolactinomas in Children and Adolescents. Clinical Presentation and Long-Term Follow-Up | 1998 | 176 | Glioma Diagnosis and Treatment |
| Dopamine D2 receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand | 1987 | 157 | Neurotransmitter Receptor Influence on Behavior |
| Effect of Different Dopaminergic Agents in the Treatment of Acromegaly | 1997 | 151 | Pituitary Gland Disorders and Treatments |
| Correlation of in Vitro and in Vivo Somatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy | 2008 | 125 | Growth Hormone and Insulin-like Growth Factors |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition and structure of Quinagolide?
Which organizations hold the most patents related to Quinagolide?
What is the trend in patent and publication activity for Quinagolide over recent years?
What are the main research topics associated with Quinagolide in the scientific literature?
What are the leading patent classification codes for intellectual property covering Quinagolide?